Transglutaminase 2 in breast cancer metastasis and drug resistance

Transglutaminase 2 (TG2) is a widely distributed multifunctional protein with various enzymatic and non-enzymatic activities. It is becoming increasingly evident that high levels of TG2 in tumors induce the occurrence of epithelial to mesenchymal transition (EMT) and the acquisition of stem cell-lik...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in cell and developmental biology 2024-10, Vol.12, p.1485258
Main Authors: Li, Mengxin, Wang, Xuanzhong, Hong, Jinghui, Mao, Juanjuan, Chen, Jiasi, Chen, Xuyang, Du, Ye, Song, Dong
Format: Article
Language:English
Subjects:
breast cancer
Cell and Developmental Biology
drug resistance
epithelial to mesenchymal transition
metastasis
transglutaminase 2
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transglutaminase 2 (TG2) is a widely distributed multifunctional protein with various enzymatic and non-enzymatic activities. It is becoming increasingly evident that high levels of TG2 in tumors induce the occurrence of epithelial to mesenchymal transition (EMT) and the acquisition of stem cell-like phenotypes, promoting tumor metastasis and drug resistance. By regulating intracellular and extracellular signaling pathways, TG2 promotes breast cancer metastasis to lung, brain, liver and bone, as well as resistance to various chemotherapy drugs including docetaxel, doxorubicin, platinum and neratinib. More importantly, recent studies described the involvement of TG2 in PD-1/PD-L1 inhibitors resistance. An in-depth understanding of the role that TG2 plays in the progression of metastasis and drug resistance will offer new therapeutic targets for breast cancer treatment. This review covers the extensive and rapidly growing field of the role of TG2 in breast cancer. Based on the role of TG2 in EMT, we summarize TG2-related signaling pathways in breast cancer metastasis and drug resistance and discuss TG2 as a therapeutic target.
ISSN:2296-634X
2296-634X
DOI:10.3389/fcell.2024.1485258